Abstract 1637P
Background
Pancreatic ductal adenocarcinoma (PDAC) has a notoriously poor prognosis after treatments without precise biomarkers. The traditional biomarker, carbohydrate antigen 19-9 is not suitable for timely checking treatment responses for all PDAC patients. The usage of low-invasive liquid biopsies, e.g., cell-free DNA (cfDNA) from blood, has shown to improve prognostication for several cancers, but not precisely for PDAC, especially for predictive prognosis by longitudinal sampling. This study aims to address the issue that the dynamic occurrence of oncogenic mutations in cfDNA from serial monitoring could be served as a predictive indicator of disease outcomes in PDAC patients after chemotherapy.
Methods
A total of 65 advanced-staged PDAC patients were enrolled. The plasma cfDNA were subjected to next generation sequencing with a panel of tumor-associated genes and confirmed by digital PCR. Patients were grouped by three risky levels which were designated by the quantities of cfDNA and presence of the oncogenic mutations in cfDNA after treatment (post-cfDNA). Association of different risk factors with progression-free survival (PFS) and overall survival (OS) was assessed in Kaplan-Meier curves and Cox regression analyses.
Results
In the prospective cohort, high-risk patients who had high levels of cfDNA over the threshold showed the worst PFS and OS [HR= 8.83 (3.99-19.51) in PFS, p<0.001; HR=4.25 (2.24-8.06) in OS, p<0.001]. The medium-risk patients, whose cfDNA levels were lower than the threshold but contained KRAS mutants in post-cfDNA, demonstrated moderately worse PFS and OS than low-risk patients without elevated levels and KRAS mutants in post-cfDNA [low risk as reference, HR= 6.08 (2.42-15.27) in PFS, p<0.001; HR=2.64 (1.18-5.91) in OS, p=0.018]. However, patients with TP53 mutants in cfDNA after treatments showed no significance correlations to either PFS (p=0.144) or to OS (p=0.098), respectively.
Conclusions
Early retention of oncogenic KRAS mutants in cfDNA after chemotherapy is an independent factor in predicting worse OS and PFS in PDAC patients. The serial molecular response of oncogenes in post-cfDNA could serve as a leading biomarker in monitoring clinical outcomes in PDAC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C-J. Huang.
Funding
National Science and Technology Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22